New Autism Drug Shows Promise in Preclinical Study

05:27 EST 14 Nov 2017 | Genetic Engineering News

Research concerning autism spectrum disorder (ASD) has seen its fair share of controversy over the years, but as researchers relentlessly pursue the underlying causes of this developmental disorder, scientific consensus and public awareness grow. Adding to the exponential growth of data for ASD, a group of investigators led by researchers at Sanford Burnham Prebys Medical Discovery Institute has just released findings from a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral and brain abnormalities in the mice.     Findings from the new study were published today in Nature Communications through an article entitled “ NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism .” NitroSynapsin is intended to restore an electrical signaling imbalance in the brain found in virtually all forms of ASD. "This drug candidate is poised to ...

Original Article: New Autism Drug Shows Promise in Preclinical Study


More From BioPortfolio on "New Autism Drug Shows Promise in Preclinical Study"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...